Prasad was first appointed head of the FDA's Center for Biologics Evaluation and Research (CBER) in May 2025 – after his ...

For the second time in less than a year, Vinay Prasad has departed from the FDA, after controversial decisions relating to the review of vaccines and rare disease therapies. Prasad was first appointed ...

Daiichi Sankyo's European division has signed a partnership with German digital health company GAIA to sell a digital ...

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A ...

So, on the strength of that trial, Blackman and Grant paid $1 million (plus $10 million in Day One stock) to Takeda and $2 ...

Chakravarthi AVPS, Chairman of the Federation of Pharma Entrepreneurs, provides an overview of global strategies to accelerate access to innovative therapies, bridging equity, regulation, and ...

Novo Nordisk has said its triple-action obesity therapy UBT251 – licensed from United Biotechnology – achieved close to 20% ...

Arbutus and Genevant's complaint claimed that Moderna's mRNA-based Spikevax shot used lipid nanoparticle (LNP) delivery ...

The FDA has started a review of Hansa Biopharma's imlifidase for patients who need a kidney transplant, but for whom finding ...

Cardiff, Wales-based Antiverse's computational platform has been set up to find antibodies against challenging drug targets, ...

United Therapeutics plans to file for approval of ralinepag as a treatment for pulmonary arterial hypertension (PAH) before ...

Roche licensed petrelintide from Zealand last year for a hefty $1.4 billion upfront payment, adding it to a portfolio of half a dozen clinical-stage candidates, including dual GIP/GLP-1 agonist CT-388 ...